NCT05270707

HyperArc Registry Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 968 (actual)
• Sponsor: Varian, a Siemens Healthineers Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Detailed description

A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Conditions

• Brain Metastases
• CNS Neoplasm
• CNS Disorder, Intracranial

Interventions

Type	Name	Description
RADIATION	Stereotactic radiosurgery	HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).

Timeline

• Start date: 2022-03-31
• Primary completion: 2025-03-31
• Completion: 2025-03-31
• First posted: 2022-03-08
• Last updated: 2025-09-24

Locations

7 sites across 4 countries: United States, Australia, Belgium, Italy

Regulatory

• FDA-regulated device study